within Pharmacolibrary.Drugs.ATC.G;

model G03AA17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AA17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Medroxyprogesterone and estradiol is a combination hormonal therapy containing a progestin (medroxyprogesterone acetate) and a natural estrogen (estradiol). It was used primarily in hormone replacement therapy for menopausal symptoms and sometimes for contraception, but combination formulations under this specific ATC code (G03AA17) are no longer widely available or commonly prescribed due to concerns about risks relating to cardiovascular events and breast cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters below are estimated using known PK profiles of the individual components (medroxyprogesterone acetate and estradiol) in healthy adult females after oral administration. No direct combination PK studies found.</p><h4>References</h4><ol><li><p>Järvinen, A, et al., &amp; Kela, M (2004). Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. <i>Maturitas</i> 47(3) 209–217. DOI:<a href=\"https://doi.org/10.1016/j.maturitas.2003.01.001\">10.1016/j.maturitas.2003.01.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15036491/\">https://pubmed.ncbi.nlm.nih.gov/15036491</a></p></li><li><p>Svensson, LO, et al., &amp; Olsson, SE (1994). Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera and Divina. A randomized, single-blind, triple cross-over bioavailability study in menopausal women. <i>Maturitas</i> 18(3) 229–238. DOI:<a href=\"https://doi.org/10.1016/0378-5122(94)90129-5\">10.1016/0378-5122(94)90129-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8015506/\">https://pubmed.ncbi.nlm.nih.gov/8015506</a></p></li><li><p>Zhou, XF, et al., &amp; Sang, GW (1998). Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. <i>Contraception</i> 57(6) 405–411. DOI:<a href=\"https://doi.org/10.1016/s0010-7824(98)00048-1\">10.1016/s0010-7824(98)00048-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9693401/\">https://pubmed.ncbi.nlm.nih.gov/9693401</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AA17;
